NEW TECHNOLOGY FOR HPV PREVENTION

Dr. Mario Tremblay, Chief Science Officer of CarraShield Labs, reviews the history of the medical research and the results of the McGill CATCH study

CarraShield Labs (CSL) has developed a personal lubricant based on a long chain polysaccharide molecule derived from a special sea algae extract called "CarraShield" that captures the HPV virus before it can infect human cells. The delivery mechanism is a pleasant to use personal lubricant. Read the research...

Results from the world's first human clinical trial involving hundreds of women show that Divine 9 with CarraShield reduces the likelihood of of HPV infection. This McGill University study is one of two human clinical trials currently underway, the other directed at gay men. The HPV prevention characteristics of Divine 9 has been previously validated by series of studies at the National Cancer Institute, Albert Einstein College of Medicine and Rutgers University Medical School.

ADVICE FOR PATIENTS

 

While the HPV vaccine  protects against at the most nine strains of the virus, potentially, the carrageenan-based lubricant can provide total protection from HPV.

Dr. Eduardo Franco, Principle Investigator, University of McGill Medical School

Given the issues with vaccines, a topical gel that can reduce HPV infection rates will revolutionize the industry..

Dr. Mark Einstein, Principle Investigator, Chair of the Dept. of Obstetrics and Gynecology, Rutgers New Jersey Medical School

The McGill University Phase 2b study results represent the first time in the history of HPV research that a topical gel in the form of a personal lubricant has been shown to  decrease the likelihood of HPV infections in women.

The CarraShield technology captures the HPV in the vaginal tract, before it attacks the cell walls. This protective barrier effect means the Divine 9 lubricant is not a drug, as it has no chemical reaction with the body.

Divine 9 is a available today to patients as an OTC personal lubricant.  Patient recommendations should be based on the fact that Divine 9 is a pleasant to use, plant-based personal lubricant that is undergoing extensive HPV prevention studies.  Combining the use of Divine 9 lubricant during sexual encounters with the proven protection of the vaccine brings together the advantages of both. 

What About Vaccines? 

The HPV vaccine is a tremendous step forward in HPV prevention but there remain issues that a protective gel can help solve...

Limited Protection For All HPV Types - Vaccines protects against, at the most, 9 of the over 150 types of HPV.

No Effect if Previously Infected - If the patient has already been exposed to one of the 9 types covered by the vaccine, then the vaccine will not protect her for that type.

Low  Uptake - Less than 5% of the world's 2.7 billion women are vaccinated.

Cost Limits Availability - Initial cost and the requirement for 2 refrigerated doses limits use in developing countries.

Fear of Side Effects - Some people refuse the vaccine because of reports of side effects.

Religious or Moral Issues - Some parents refused to vaccinate their children because of sexual connotations.

Only 107 Million Women are Vaccinated

CARRASHIELD LABS COMPANY INFORMATION

 

The team at CarraShield Labs, has been working with world class HPV research teams for over a decade. Intensive effort has led to a personal lubricant product formulated with CarraShield®, a safe, natural ingredient that has been shown to help block human papillomaviruses (HPV) in laboratory, animal and human clinical tests. 

 

Divine 9 with CarraShield is a breakthrough for people concerned about their sexual wellness and something you can recommend to patients both for their enjoyment and for the potential health benefits.

 

Count on CarraShield Labs to continue to bring you innovative products like Divine 9 with CarraShield.

McGILL MEDICAL SCHOOL STUDY ON WOMEN

 

McGill Medical School published the first set of results of their HPV prevention study on women using on Divine 9 personal lubricant with each sexual encounter and they found:

"(Our) interim analysis suggests that using (Divine 9) lubricant gel can reduce the risk of genital HPV infections in women." 

McGill University Medical School

The McGill University Medical School study to reduce HPV infections through use of Divine 9® personal lubricant has yielded compelling results.  Based on data from 280 participants, the women using the Divine 9 personal lubricant with proprietary CarraShield® plant extract had fewer new HPV infections over a 6 to 12 month period as compared to women using a placebo lubricant. 

 

These new results represent the first time in the history of HPV research that a topical gel in the form of a personal lubricant has been shown to significantly decrease the number of HPV infections in women.

 

The study is called CATCH, an acronym for Carrageenan-gel Against Transmission of Cervical HPV, and involves tracking HPV infections in over four hundred female volunteers for a one year period. Divine 9 was the only personal lubricant selected for the trial

The McGill University research team is led by Dr. Eduardo Franco, Director of the Division of Cancer Epidemiology. Dr. Franco, a renowned expert on the prevention of cervical cancer and HPV-associated diseases, has published over 400 scientific articles. 


Dr. Eduardo Franco, Chair of the Department of Oncology at McGill University, Talks About HPV and the CATCH Study using Divine 9

The CATCH study is a major initiative to determine if using a carrageenan-based gel can prevent the acquisition and transmission of HPV in a real world setting.  If the trial is successful, it would mean that women have another option for protecting themselves against HPV, the causative agent for cervical cancer.

Dr. Eduardo Franco, Principle Investigator, University of McGill Medical School

McGILL STUDY ON GAY MEN

 

McGill University's Study on Preventing HPV Transmission among Gay and Bisexual Men

McGill University Medical School’s Division of Cancer Epidemiology is running a large-scale study on the ability of Divine 9® personal lubricant, made with CarraShield®, to block the transmission of HPV in gay and bisexual men. HPV is a serious health risk for the gay and bisexual community as it causes throat, anal and penile cancers as well as genital warts.

 

This latest McGill study is called “LIMIT-HPV,” an acronym for Lubricant Investigation in Men to Inhibit Transmission of HPV. The LIMIT-HPV study will involve tracking the presence of HPV infections in over two hundred male volunteers for a one year period. As with McGill University’s earlier CATCH study investigating the ability of CarraShield to prevent HPV infections in women, the LIMIT-HPV research will focus on determining the protective capabilities of CarraShield in the Divine 9 lubricant as compared to a placebo lubricant using a double blind procedure.  Participants are instructed to use the lubricant as they normally would in an intimate encounter. Earlier research suggests the CarraShield in Divine 9 creates a protective barrier that traps the virus and thereby prevents infection.

McGill LIMIT HPV Clinical Trial on Gay Men for HPV Reduction

AECOM INHIBITION TIME STUDY

 

Albert Einstein College of Medicine (AECOM) and Rutgers University Research on Effectiveness of Divine 9 in Woman From Time of Application

Both the Albert Einstein College of Medicine (AECOM) at Yeshiva University in New York City as well at the Rutgers New Jersey Medical School have conducted studies to determine the ability to reduce transmission of HPV using Divine 9 personal lubricant made with a special sea algae extract called CarraShield.

 

Funded by the National Cancer Institute through a multi-million dollar grant, the studies at AECOM and Rutgers were a two-phase laboratory and clinical trial to determine how well Divine 9 personal lubricant works to block HPV.  In the first set of published results, AECOM partnered with the non-profit Population Council to compare Divine 9 with a gel the Population Council had used in HIV prevention studies. Read the full journal article...

 

The second study conducted at AECOM was a human clinical study to determine Divine 9's inhibitory effect over time. AECOM recruited participants who applied Divine 9, engaged in a sexual encounter, and then were analyzed hours later.  Samples of Divine 9 were taken from the vaginal tracts of the participants and subjected to laboratory challenge tests with HPV. The researchers found the inhibition effect of Divine 9 was active in the women more than 8 hours after initial application.   Read the full journal article...

The principal investigator for the studies was Mark Einstein, M.D., M.S., and formerly Professor of Obstetrics & Gynecology and Women’s Health and Professor of Epidemiology & Population Health at the Albert Einstein College of Medicine and now Chair of the OB/GYN & Women’s Health Department at Rutgers Medical School. Dr. Einstein is one of the world’s leading authorities on cervical cancer prevention and consults with the World Health Organization, National Cancer Society and Society of Gynecologic Oncology.

Rutgers Medical School and Albert Einstein College of Medicine Logos

STUDIES BY THE NATIONAL CANCER INSTITUTE

 

Laboratory Studies at the National Cancer Institute Found That Divine 9 Lubricant Blocked HPV in both the Laboratory and in Mice

A July 14, 2006 research paper titled Carrageenan Is a Potent Inhibitor of Papillomavirus Infection by Christopher B. Buck, Cynthia D. Thompson, Jeffrey N. Roberts, Martin Müller, Douglas R. Lowy and John T. Schiller demonstrated the amazing potential of Divine products to block viruses that cause cancers. The article was published in the Public Library of Science.

The research revealed that carrageenan is an exceptionally potent inhibitor of papillomavirus infectivity and that Divine 9 products were more effective than any other product tested. 

 

In a second 2007 study titled Genital Transmission of HPV in a Mouse Model is Potentiated by Nonoxynol-9 and Inhibited by Carrageenan, the research team of Jeffrey Roberts, Christopher Buck, Cynthia Thompson, Rhonda Kines, Marcelino Bernardo, Peter L. Choyke, Douglas R. Lowy & John T. Schiller made an extraordinary series of revelations using in vivo testing with mice.  

 

First they found that the common spermicide Nonoxynol-9 actually increased the likelihood of HPV infection significantly. They also found that carrageenan in general, and Divine 9 specifically, virtually eliminated HPV infection in the mice. Finally, they found that when a carrageenan based product like Divine 9 is combined with Nonoxynol-9, the likelihood of HPV infection is once again reduced significantly.

 

While this study was not conducted on humans, the conclusion is still thought provoking. Using Nonoxynol-9 as a spermicide for birth control has the potential to increase the chances of being infected by HPV. However, when combined with Divine 9 with CarraShield, the risk of infection might be reduced.

(1) Holmes KK, Levine R, Weaver M (2004) Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 82: 454–461.

Nature-Medicine---Genital-Tranmission-of
Nature-Medicine---Genital-Tranmission-of

WHAT PEOPLE ARE SAYING...

1/4

CONNECT WITH DIVINE 9

  • Facebook Classic
  • Twitter Classic

CONTACT CARRASHIELD LABS WITH QUESTIONS, SUGGESTIONS OR ISSUES AND WE WILL BE GLAD TO HELP

© 2000-2017 CarraShield Labs, Inc.